Insights

Innovative Therapeutics Xbiome's advanced AI-driven microbiome platform positions it at the forefront of personalized gut health treatments, creating opportunities to collaborate with pharmaceutical companies seeking cutting-edge solutions for microbiome-related diseases.

Strategic Asset Acquisition The company's recent acquisition of the clinical-stage M201 program from Assembly Biosciences indicates its commitment to expanding its pipeline, presenting potential partnership and licensing opportunities for organizations interested in microbiome therapeutics.

Robust Funding With a recent Series B financing of 100 million dollars, Xbiome has substantial financial backing, enabling large-scale clinical development and offering prospects for joint ventures and co-investment in innovative microbiome research projects.

Collaborative Ventures Xbiome's partnership with Aurealis Therapeutics to develop and market AUP-16 four-in-one therapy in Greater China highlights its openness to strategic collaborations, which could be leveraged for regional or technological expansion initiatives.

Target Market Potential Operating in the rapidly growing field of microbiome therapeutics with a focus on gut health, Xbiome's market position indicates significant sales opportunities across biotech, pharma, and healthcare sectors seeking microbiome-based solutions for various diseases.

Xbiome Tech Stack

Xbiome uses 8 technology products and services including Vue.js, jQuery, Swiper, and more. Explore Xbiome's tech stack below.

  • Vue.js
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • Swiper
    Javascript Libraries
  • jQuery UI
    Javascript Libraries
  • PHP
    Programming Languages
  • Bootstrap
    UI Frameworks
  • Nginx
    Web Servers
  • Apache
    Web Servers

Media & News

Xbiome's Email Address Formats

Xbiome uses at least 1 format(s):
Xbiome Email FormatsExamplePercentage
LastFirst@xbiome.comDoeJohn@xbiome.com
50%
FirstL@xbiome.comJohnD@xbiome.com
31%
FirstLast@xbiome.comJohnDoe@xbiome.com
16%
FirLast@xbiome.comJohDoe@xbiome.com
3%

Frequently Asked Questions

Where is Xbiome's headquarters located?

Minus sign iconPlus sign icon
Xbiome's main headquarters is located at Cambridge, Massachusetts US. The company has employees across 3 continents, including AsiaNorth AmericaEurope.

What is Xbiome's official website and social media links?

Minus sign iconPlus sign icon
Xbiome's official website is xbiome.com and has social profiles on LinkedInCrunchbase.

What is Xbiome's SIC code NAICS code?

Minus sign iconPlus sign icon
Xbiome's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Xbiome have currently?

Minus sign iconPlus sign icon
As of December 2025, Xbiome has approximately 53 employees across 3 continents, including AsiaNorth AmericaEurope. Key team members include Cto: H. H.Chief Scientific Officer: C. B.Chief Medical Science Advisor: S. W.. Explore Xbiome's employee directory with LeadIQ.

What industry does Xbiome belong to?

Minus sign iconPlus sign icon
Xbiome operates in the Biotechnology Research industry.

What technology does Xbiome use?

Minus sign iconPlus sign icon
Xbiome's tech stack includes Vue.jsjQuerySwiperjQuery UIPHPBootstrapNginxApache.

What is Xbiome's email format?

Minus sign iconPlus sign icon
Xbiome's email format typically follows the pattern of LastFirst@xbiome.com. Find more Xbiome email formats with LeadIQ.

How much funding has Xbiome raised to date?

Minus sign iconPlus sign icon
As of December 2025, Xbiome has raised $100M in funding. The last funding round occurred on Dec 22, 2021 for $100M.

When was Xbiome founded?

Minus sign iconPlus sign icon
Xbiome was founded in 2017.

Xbiome

Biotechnology ResearchMassachusetts, United States51-200 Employees

As the leading AI-based microbiome drug development company in China, Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut health of human being with medical treatments and precise and personalized management.

The gut is the largest microbial ecosystem in the human body. It hosts about 100 trillion microbes – 500 – 1000 unique species, and contains 150-fold more genes than the human genome, which influence the human health systematically. Studies show that more than 50 human diseases are associated with dysbiosis of gut microbiota.

Unlike the traditional paradigm of drug discovery, Xbiome's approach innovatively combines microbial technologies, artificial intelligence, bioinformatics analysis and gut microbiome technologies into a unique drug development platform, which substantially speeds up and improves the success rate of new drug development.

Section iconCompany Overview

Headquarters
Cambridge, Massachusetts US
Website
xbiome.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $100M

    Xbiome has raised a total of $100M of funding over 4 rounds. Their latest funding round was raised on Dec 22, 2021 in the amount of $100M.

  • $100M$250M

    Xbiome's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $100M

    Xbiome has raised a total of $100M of funding over 4 rounds. Their latest funding round was raised on Dec 22, 2021 in the amount of $100M.

  • $100M$250M

    Xbiome's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.